Could Making Cancer Screening Simpler Increase Women's Risk?

By:

Tara Haelle

A proposal to simplify cervical cancer screening could end up missing some cancers, researchers and patient advocates say. And that could be especially true for minority women.

Latina and black women already have the highest rates of cervical cancer in the U.S., and more than half of women with the disease were not screened in the five years before their diagnosis, according to the Centers for Disease Control and Prevention.

In September, the influential U.S. Preventive Services Task Force issued draft recommendations for women ages 30 to 64, saying they could either get a Pap smear every three years or a human papillomavirus test every five years. (The task force did not recommend changes for any other ages.) That is a change from the 2012 guidelines, which recommended undergoing both the HPV and Pap tests every five years. And that's what two dozen other medical organizations still recommend.

In 2014, 12,578 U.S. women were diagnosed with cervical cancer and 4,115 died, according to the CDC. But those numbers obscure demographic disparities.

"We are concerned about the women who basically will fall through the cracks if co-testing does not continue to be recommended and therefore reimbursed" by insurance companies, says Carolyn R. Aldigé, the president and founder of the Prevent Cancer Foundation, who wrote an op-ed supporting continued use of testing for both. "We're particularly concerned about medically underserved women who have less access to screening in general and higher rates of cervical cancer."

The task force has extended the deadline for comments on the proposed change until Friday at 8 p.m. ET. They can be filed online.

According to CDC data, Latina women have the highest rate of cervical cancer in the country. Black women have the second highest cancer rate but are more likely than Latina women to die of the disease. Limiting access to screening, especially for these groups, is "the wrong direction to go in," Aldigé says.

In a statement to the task force from the National Latina Institute for Reproductive Health, Ann Marie Benitez, the organization's senior director of governmental affairs and a cervical cancer survivor, pointed out the systemic barriers Latina women face in getting adequate preventive care and the research that supports testing for both.

"The largest retrospective study of cervical cancer screening strategies found that 1 out of 5 cases of cervical cancer was missed with primary HPV screening alone," Benitez's statement reads. "The USPSTF recommendations for screening must be revised to address the reality that many women at higher risk would be missed with less frequent and less comprehensive screening. Changes in this policy would put the lives of women of color further at risk."

The task force relied on seven randomized controlled trials and five observational studies for their decision. Six of the randomized controlled trials were European — from England, Finland, the Netherlands, Sweden and two from the same group in Italy — and one was Canadian. Most of these countries have predominantly white populations, and only the Canadian study reported participants' race or ethnicity. The task force also noted their evidence review had no trials that directly compared HPV testing alone with testing for both. Yet the draft recommendations include HPV testing alone as a screening option, something no other medical organizations currently recommend.

The trials' testing methods also differ from tests used in the U.S. standard of care, according to Dr. Harvey Kaufman, medical director at Quest Diagnostics, a large medical testing company. Neither of the two HPV tests used in the studies is the one approved for primary HPV testing in the U.S., he says, and five of the seven studies used different types of Pap tests.

Kaufman also described inconsistencies in the way the task force selectively used data.

"In creating their model, they had to make assumptions about the sensitivity and specificity of cytology, HPV and co-testing," Kaufman says. Sensitivity and specificity are two ways to measure a screening test's accuracy. The task force used different studies for these numbers and then made calculations to adjust them for comparison.

"The mathematical gymnastics core to their model is not supported by statistical approaches in any textbooks I've seen," Kaufman says. Even with their calculations, he says, an estimated 5 percent of women with cervical disease would be missed by HPV testing but identified with testing for both — and those are the women getting tested regularly.

"In real life, particularly in the U.S. where we have a more fragmented health system, you have to build a model that acknowledges the realities of how frequently people really do show up," Kaufman says.

The task force listed the main harms of screening as false positives that could lead to excess follow-up tests and colposcopies. They acknowledge that "false-positive rates are higher among women younger than age 30 years compared with older women because of the higher incidence of transient HPV infection in younger women." The populations in studies they used included women ages 21 to 65, but the recommendations for women ages 21 to 29 remain unchanged — Pap test alone every three years.

For the task force, says Aldigé, "the risk of overtreatment seems to outweigh the risk of missing cancers, whereas we feel that missing a significant number of cancers outweighs the risk of overtreatment." She also worries about the effect of yet another change in recommendations, which have already undergone frequent changes in recent years.

"It throws women into a state of confusion," Aldigé says. "The recommendations are constantly changing and women don't know what to do, and sometimes when people don't know what to do, they do nothing."

Maureen Phipps, chair of obstetrics and gynecology at the Warren Alpert Medical School of Brown University in Providence, R.I., and a member of the task force, says the task force will take whatever time is necessary to read all public comments before deciding whether to adopt or revise their proposed recommendations.

Aldigé and Kaufman hope the task force will revert to keeping testing for both for women ages 30 to 64.

"One of the most notable success stories in all of health care is the fact that we have reduced the number of deaths from cervical cancer so dramatically," Aldigé says. "We need to appreciate what screening has been able to accomplish in terms of public health. We can continue to bring those numbers down with co-testing."

Upcoming Events

The Retro Cocktail Hour's Cinema a Go-Go series returns to Liberty Hall with a night of extraterrestrial bad guys! Our big double feature has two of the original "alien invasion" movies of the early 1950s, including Howard Hawks' production of the original The Thing From Another World (1951) and low budget auteur Edgar G. Ulmer's The Man From Planet X(1951).

Will Earth survive? Join us and find out at Cinema a Go-Go - and be sure to enter our intermission giveaway when we'll be handing out all manner of otherworldly goodies from the RCH Warehouse.

Join us at Liberty Hall in downtown Lawrence, Friday, October 20. Tickets are $8, available at the doors, which open at 6:30 p.m.

You can buy reserved seats on the floor, either as a table of 10 ($300), a table of 4 ($120), or individual reserved seats ($30). Seating in the balcony is general admission and run $20 a ticket. The dance floor will be open to balcony and floor seating. A service charge may be added to your order. Tickets are available at the Liberty Hall box office or ticketmaster.com. Tickets will also be available the night of the concert. The Liberty Hall ticket office is cash only.

Ron Gutierrez joins the fun again this year. His rich, soulful vocals and vast repertoire have led to performances alongside such artists as Michael McDonald, Wynonna Judd, Rita Moreno and B.B. King, as soloist with The National Symphony Orchestra and during national television appearances on such shows as “Showtime at the Apollo” and numerous PBS concerts.

Kathleen Holeman has been performing for more than 20 years as a solo act, sideman and leader of jazz groups of all sizes. She’s led the Ray Alburn Big Band since June 2007. She’s been a private music teacher for 20 years and on the faculty at Missouri Western State University since 2008.

Formed in 2003, the Kansas City Jazz Orchestra brings many of the region's greatest jazz musicians together to perform big band jazz in a concert setting. The KCJO is under the direction of Clint Ashlock, Kansas City native and trumpeter.

Description: Celebrate the launch of the sun and her flowers, the long awaited second collection of poetry from Rupi Kaur, the No. 1 New York Times bestselling author of milk and honey. Rupi Kaur’s new softcover the sun and her flowers and one admission ticket is included with each Admission Package Purchase. Admission packages are $28.50 plus applicable fees, and go on sale at 10 a.m. Friday, September 15. Tickets will be available through the Kauffman Center Box Office at (816) 994-7222, via the Kauffman Center mobile app, or online at www.kauffmancenter.org. Kaur views her life as an exploration of that artistic journey. She published her first collection of poems, milk and honey, in 2014. The internationally acclaimed collection sold well over a million copies, gracing the New York Times bestsellers list every week for over a year. It has since been translated into over thirty languages. Kaur’s long-awaited second collection, the sun and her flowers, will be released in October 2017. Through this collection Kaur continues to explore a variety of themes including love, loss, trauma, healing, femininity, migration and revolution. The event is presented in partnership Andrews McMeel Universal and Rainy Day Books. More information and tickets: http://tickets.kauffmancenter.org/single/eventDetail.aspx?p=12966 Submitted by: Eliza Scott Kauffman Center for the Performing Arts